Biology of Blood and Marrow Transplantation
Volume 13, Issue 7 , Pages 838-843 , July 2007

Phase I Trial of Parathyroid Hormone to Facilitate Stem Cell Mobilization

  • Karen K. Ballen

      Affiliations

    • Hematology/Oncology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
    • Corresponding Author InformationCorrespondence and reprint requests: Karen Ballen, M.D., Division of Hematology/Oncology, Massachusetts General Hospital, Zero Emerson Place, Suite 118, Room 134, Boston, MA 02114.
    • ,
  • Elizabeth J. Shpall

      Affiliations

    • M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • David Avigan

      Affiliations

    • Division of Hematologic Malignancies, Beth Israel Deaconess Medical Center, Boston, Massachusetts
    • ,
  • Beow Y. Yeap

      Affiliations

    • Hematology/Oncology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
    • ,
  • David C. Fisher

      Affiliations

    • Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Kathleen McDermott

      Affiliations

    • Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Bimalangshu R. Dey

      Affiliations

    • Hematology/Oncology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
    • ,
  • Eyal Attar

      Affiliations

    • Hematology/Oncology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
    • ,
  • Steven McAfee

      Affiliations

    • Hematology/Oncology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
    • ,
  • Marina Konopleva

      Affiliations

    • M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Joseph H. Antin

      Affiliations

    • Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Thomas R. Spitzer

      Affiliations

    • Hematology/Oncology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts

Received 13 December 2006 ,Accepted 16 March 2007.

References 

  1. Narayanasami U, Konteti R, Morelli J, et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood. 2001;98:2059–2064
  2. Koc O, Gerson SC, Cooper BW, et al. Rapid hematopoietic recovery after co-infusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high dose chemotherapy. J Clin Oncol. 2000;18:307–316
  3. Carlo-Stella C, Di Nicola M, Milani R, et al. Use of granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers. Blood. 2004;104:3287–3295
  4. Morris CL, Siegel E, Barlogie B, et al. Mobilization of CD34+ cells in elderly patients (>70 years old) with multiple myeloma: influence of age, prior therapy, platelet count, and mobilization regimen. Br J Hematother. 2003;120:413–423
  5. Gordan LN, Sugrue MW, Lynch JW, et al. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leukemia Lymphoma. 2003;44:815–820
  6. Calvi LM, Adams GB, Welbrecht KW, et al. Osteoblastic cells regulate the hematopoietic stem cell niche. Nature. 2003;425:841–846
  7. Zhang J, Niu C, Huang H, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature. 2003;425:836–841
  8. Taichman RS, Reilly MJ, Emerson SG. Human osteoblasts support human hematopoietic progenitor cells in vitro bone marrow cultures. Blood. 1996;87:518–524
  9. Taichman RS, Emerson SJ. Human osteoblasts support the production of granulocyte colony-stimulating factor. J Exp Med. 1994;179:1677–1682
  10. Karanu FN, Murdoch B, Gallacher C, et al. The notch ligand Jagged-1 represents a novel growth factor of human hematopoietic stem cells. J Exp Med. 2000;192:1365–1372
  11. Taichman RS. Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche. Blood. 2005;105:2631–2639
  12. Zhu J, Zhang Y, Joe GJ, et al. NF-Ya activates multiple hematopoietic stem cell (HSC) regulatory genes and promotes HSC self-renewal. Proc Natl Acad Sci. 2005;102:11728–11733
  13. Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD 3100 to patients with multiple myeloma and non Hodgkin’s lymphoma. J Clin Oncol. 2004;22:1095–1102
  14. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD 3100, a CXCR4 antagonist. Blood. 2003;102:2728–2730
  15. Stier S, Chen T, Dombkowski D, et al. Notch 1 activation increases hematopoietic stem cell self-renewal in vivo and favors lymphoid over myeloid lineage outcome. Blood. 2002;99:2369–2372
  16. Jung Y, Wang J, Schneider A, et al. Regulation of SDF-1 (CXCL12) production by osteoblasts; a possible mechanism for stem cell homing. Bone. 2006;38:497–508
  17. Finkelstein JS, Klibanski A, Arnold AL, et al. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone: a randomized controlled trial. JAMA. 1988;280:1067–1073
  18. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–1441
  19. Finkelstein JS, Hayes A, Hunzelman L, et al. The effect of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003;349:1207–1215
  20. Black DM, Greensplan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination with postmenopausal osteoporosis. N Engl J Med. 2003;349:1207–1215
  21. Adams GB, Martin RP, Alley IR, et al. Therapeutic targeting of a stem cell niche. Nat Biotechnol. 2007;25:238–243
  22. Fu P, Bagai PK, Meyerson H, et al. Pre-mobilization therapy blood CD34+ cell count predicts the likelihood of successful hematopoietic stem cell mobilization. Bone Marrow Transplant. 2006;38:189–196
  23. Weaver CH, Tauer K, Zhen B, et al. Second attempts at mobilization of peripheral blood stem cells in patients with initial low CD34+ cell yields. J Hematother. 1998;7:241–249
  24. Bashey A, Corringham S, Gilpin E, et al. Simultaneous administration of G-CSF and GM-CSF for re-mobilization in patients with inadequate progenitor cell collections for autologous transplantation. Cytotherapy. 2000;2:195–200
  25. Goterris R, Hernadez-Bolida JC, Teruel A, et al. Impact of different strategies of second-line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobilizers. Bone Marrow Transplant. 2005;36:847–853
  26. Parkins MD, Bahlis N, Brown C, et al. Overnight storage of autologous stem cell apheresis products before cryopreservation does not adversely impact early or long-term engraftment following transplantation. Bone Marrow Transplant. 2006;38:609–614
  27. Ballen KK. New trends in umbilical cord blood transplantation. Blood. 2005;105:3786–3792
  28. Barker JN, Weisdorf DF, DeFor TE. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood. 2003;102:1915–1919
  29. Ballen KK, Spitzer TR, Yeap B, et al. Double unrelated reduced intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant. 2007;13:82–89

PII: S1083-8791(07)00216-9

doi: 10.1016/j.bbmt.2007.03.007

Biology of Blood and Marrow Transplantation
Volume 13, Issue 7 , Pages 838-843 , July 2007

Article Tools